Priority Date: 02.07.14 (US 201462019925P)

PHARMACEUTICAL COMPOSITION COMPRISING RECOMBINANT HEMOGLOBIN PROTEIN OR SUBUNIT-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT

  • Application ID: EP15815035
  • Status: EXAMINATION REQUESTED

Attorney

no operation time available
3 offices
active in Legal Services

Specialization

This EP application has the IPC combination A61, C07, and G01. We found, that TransMIT GmbH, Kailuweit & Uhlemann, dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB, Avidity IP Ltd, Mewburn Ellis LLP and 54 others are specialized in this combination either. For a similar patent, they might be a good choice.

Timeline

  • 02.07.2014 - Priority Date (US 201462019925P)
  • 07.01.2016 - Publication A1 (WO2016000616)
  • 10.05.2017 - Publication A1 (EP3164412)